Who We Are
Phanes Therapeutics is an innovative drug discovery company that develops therapies to treat solid tumors and eye diseases. At Phanes, we believe that strong science is the basis for innovation and only people with passion and resilience can deliver ground-breaking results. Through innovation, we aim to solve some of the most difficult scientific problems in the biopharma industry. Our goal is to become an important source of innovative molecules and deliver some of the most robust therapies to improve patients’ lives.
Our first-in-class molecules include a monoclonal antibody for solid tumors as well as age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), and a bispecific antibody targeting small cell lung cancer (SCLC). Our best-in-class monoclonal antibodies are designed to deliver real benefits to patients with clinically meaningful differentiation in safety or efficacy. Our innovation is also reflected by several lead molecules in the bispecific antibody and single-chain variable fragment (scFv) programs in our pipeline.
At Phanes, we understand that scientific innovation is a challenging task and we need the most talented people to accomplish our mission. We are committed to fostering an innovative environment and building a healthy scientific ecosystem for the next generation of scientific and business leaders, because we know that our success depends on how to realize the true potential of our people.
The company was incorporated in 2016.
The company is led by a strong scientific team with broad pharma and biotech experience.
The company is supported by a group of top industry advisers.
The company is located in San Diego, one of the major biotech hubs.